Table of contents
From the editors
p901 | doi:10.1038/nrc2558
Research Highlights
Tumorigenesis: Domain game | PDF (146 KB)
p903 | doi:10.1038/nrc2548
Aneuploidy: Hyperactivity disorder | PDF (167 KB)
p904 | doi:10.1038/nrc2549
Genomic instability: Another string to the bow | PDF (178 KB)
p904 | doi:10.1038/nrc2555
Glioblastoma: Stop acting so immature | PDF (155 KB)
p905 | doi:10.1038/nrc2546
Signalling: Making more of a mark | PDF (180 KB)
p906 | doi:10.1038/nrc2551
Immunotherapy: It pays to be persistent | PDF (180 KB)
p906 | doi:10.1038/nrc2554
In the news
Engineering a better diet | PDF (90 KB)
p906 | doi:10.1038/nrc2557
In brief
Apoptosis | Tumour biology | Gene profiling | PDF (131 KB)
p907 | doi:10.1038/nrc2553
Stem cells: A new pathway for stem cell ageing and renewal | PDF (152 KB)
p908 | doi:10.1038/nrc2547
Tumour supression: Lost in translation | PDF (167 KB)
p908 | doi:10.1038/nrc2550
Tumour microenvironment: There goes the neighbourhood | PDF (209 KB)
p908 | doi:10.1038/nrc2556
Trial Watch
KRAS mutations and cetuximab | Cancer prevention trial halted | PDF (121 KB)
p909 | doi:10.1038/nrc2552
Progress
Non-coding RNA production by RNA polymerase III is implicated in cancer
Lynne Marshall & Robert J. White
p911 | doi:10.1038/nrc2539
Increased RNA polymerase III activity in cancer has been observed for over 30 years but how this occurs and affects cellular transformation is only beginning to be understood. Lynne Marshall and Robert J. White discuss recent progress made in this emerging field.
Reviews
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
p915 | doi:10.1038/nrc2536
Insulin and insulin-like growth factors (IGFs) are well-known as key regulators of energy metabolism and growth and have important roles in neoplasia. This Review documents the various methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signalling.
There is an Erratum (1 March 2009) associated with this article
The ADAMs: signalling scissors in the tumour microenvironment
Gillian Murphy
p932 | doi:10.1038/nrc2459
The disintegrin metalloproteinases of the Adam (a disintegrin and metalloproteinase) family mediate proteolytic 'shedding' of membrane-associated proteins and hence rapidly modulate key cell signalling pathways in the tumour microenvironment. What is the biological and clinical relevance of the ADAMs?
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer, Massimiliano Mazzone, Bart Jonckx & Peter Carmeliet
p942 | doi:10.1038/nrc2524
Anti-angiogenic drugs have become part of the standard therapeutics used to treat cancer. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles. Will other agents with complementary mechanisms offer novel opportunities for improved treatment?
Perspectives
Opinion
H2AX and cancer
William M. Bonner, Christophe E. Redon, Jennifer S. Dickey, Asako J. Nakamura, Olga A. Sedelnikova, Stéphanie Solier & Yves Pommier
p957 | doi:10.1038/nrc2523
DNA double strand breaks (DSBs) may lead to cancer but, paradoxically, are also used to kill cancer cells. How might 
H2AX — a surrogate marker of DSBs — be used to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs?
Article series: Hypoxia and metabolism
Timeline
The impact of O2 availability on human cancer
Jessica A. Bertout, Shetal A. Patel & M. Celeste Simon
p967 | doi:10.1038/nrc2540
During the past century, the response to hypoxia has emerged as an important phenotypic determinant of a tumour, with repercussions for sensitivity to radiation and chemotherapy. This Timeline provides a historical overview of responses to hypoxia while looking forward to therapeutic strategies that are being developed to exploit them.
Article series: MYC
Timeline
Reflecting on 25 years with MYC
Natalie Meyer & Linda Z. Penn
p976 | doi:10.1038/nrc2231
MYC is an iconic oncogene that has been at the forefront of cancer research since its discovery. Looking back over the history of MYC research provides us with a framework with which to progress in the next 25 years, as outlined in this Timeline.
Correspondence
Correspondence: On clonogenic tumour cells and metastasis-forming cells
Maurice Tubiana & Serge Koscielny
p990 | doi:10.1038/nrc2419-c1
Correspondence: Clonogens and cancer stem cells
Michael Baumann, Mechthild Krause & Richard Hill
p990 | doi:10.1038/nrc2419-c2
